LTRNClinical Trials•businesswire•
Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors
Sentiment:Positive (78)
Summary
(NASDAQ:LTRN) DALLAS--(BUSINESS WIRE)--Clinical Trial Results, LP-184
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 16, 2025 by businesswire